Kinase drug discovery 20 years after imatinib: progress and future directions

por Cohen, Philip, Cross, Darren, Jänne, Pasi A.
Publicado 2021

Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma

por Martin, Matthew J., Eberlein, Cath, Taylor, Molly, Ashton, Susan, Robinson, David, Cross, Darren
Publicado 2016

Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors

por Sommer, Eeva M., Dry, Hannah, Cross, Darren, Guichard, Sylvie, Davies, Barry R., Alessi, Dario R.
Publicado 2013

The hVps34‐SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth

por Bago, Ruzica, Sommer, Eeva, Castel, Pau, Crafter, Claire, Bailey, Fiona P, Shpiro, Natalia, Baselga, José, Cross, Darren, Eyers, Patrick A, Alessi, Dario R
Publicado 2016

Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III pho...

por Bago, Ruzica, Malik, Nazma, Munson, Michael J., Prescott, Alan R., Davies, Paul, Sommer, Eeva, Shpiro, Natalia, Ward, Richard, Cross, Darren, Ganley, Ian G., Alessi, Dario R.
Publicado 2014

Efficacy of osimertinib against EGFRvIII+ glioblastoma

por Chagoya, Gustavo, Kwatra, Shawn G., Nanni, Cory W., Roberts, Callie M., Phillips, Samantha M., Nullmeyergh, Sarah, Gilmore, Samuel P., Spasojevic, Ivan, Corcoran, David L., Young, Christopher C., Ballman, Karla V., Ramakrishna, Rohan, Cross, Darren A., Markert, James M., Lim, Michael, Gilbert, Mark R., Lesser, Glenn J., Kwatra, Madan M.
Publicado 2020

Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer

por Adua, Sally J., Arnal-Estapé, Anna, Zhao, Minghui, Qi, Bowen, Liu, Zongzhi Z., Kravitz, Carolyn, Hulme, Heather, Strittmatter, Nicole, López-Giráldez, Francesc, Chande, Sampada, Albert, Alexandra E., Melnick, Mary-Ann, Hu, Bomiao, Politi, Katerina, Chiang, Veronica, Colclough, Nicola, Goodwin, Richard J. A., Cross, Darren, Smith, Paul, Nguyen, Don X.
Publicado 2022

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON

por Hartmaier, Ryan J., Markovets, Aleksandra A., Ahn, Myung Ju, Sequist, Lecia V., Han, Ji-Youn, Cho, Byoung Chul, Yu, Helena A., Kim, Sang-We, Yang, James Chih-Hsin, Lee, Jong-Seok, Su, Wu-Chou, Kowalski, Dariusz M., Orlov, Sergey, Ren, Song, Frewer, Paul, Ou, Xiaoling, Cross, Darren A.E., Kurian, Nisha, Cantarini, Mireille, Jänne, Pasi A.
Publicado 2023

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer

por Eser, Pınar Özden, Paranal, Raymond M., Son, Jieun, Ivanova, Elena, Kuang, Yanan, Haikala, Heidi M., To, Ciric, Okoro, Jeffrey J., Dholakia, Kshiti H., Choi, Jihyun, Eum, Yoonji, Ogino, Atsuko, Missios, Pavlos, Ercan, Dalia, Xu, Man, Poitras, Michael J., Wang, Stephen, Ngo, Kenneth, Dills, Michael, Yanagita, Masahiko, Lopez, Timothy, Lin, Mika, Tsai, Jeanelle, Floch, Nicolas, Chambers, Emily S., Heng, Jennifer, Anjum, Rana, Santucci, Alison D., Michael, Kesi, Schuller, Alwin G., Cross, Darren, Smith, Paul D., Oxnard, Geoffrey R., Barbie, David A., Sholl, Lynette M., Bahcall, Magda, Palakurthi, Sangeetha, Gokhale, Prafulla C., Paweletz, Cloud P., Daley, George Q., Jänne, Pasi A.
Publicado 2021